Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
Guangzhou Military Region General Hospital, Department of Anesthesiology, Guangzhou, Guangdong, China
DMC Surgery Hospital, Madison Heights, Michigan, United States
Texas Children't Hospital, Houston, Texas, United States
Asklepieion Hospital of Voula, Athens, Attica, Greece
Nanjing Maternity and Child Health Care Hospital, Nanjing, Jiangsu, China
Changi General Hospital, Singapore, Singapore
General Surgery Ward, Poriya, The Lower Galilee, Israel
Seoul National University Bundang Hospital, Sungnam, Gyungido, Korea, Republic of
CCOM-Hôpitaux Universitaires de Strasbourg, Illkirch-Graffenstaden, France
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.